SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to...
Introducing a mammal-derived genome engineering enzyme for next-generation gene and cell therapy Financing to fund SalioGen’s pipeline in genetic diseases, based on proprietary EDIT ‘gene coding’...
View ArticleSalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing...
CAMBRIDGE, Mass. – January 05, 2022 – SalioGen Therapeutics, a privately held biotechnology company developing Gene CodingTM, a new category of genetic medicine, today announced the completion of an...
View ArticleSalioGen Therapeutics Appoints Jason F. Cole as Chief Executive Officer and...
Biotech industry veteran strengthens leadership team with decades of experience Lexington, Mass. – September 11, 2023 – SalioGen Therapeutics, a privately held biotechnology company, today announced...
View ArticleSalioGen Therapeutics Announces Selection of Development Candidate for...
SGT-1001 is the first development candidate using SalioGen’s novel Gene CodingTM technology for gene integration via transposition SalioGen plans to advance SGT-1001 into the clinic in the first half...
View ArticleSalioGen Therapeutics Announces Data Presentations at 2024 Annual Meetings...
Company to present pre-clinical data on Stargardt disease development candidate SGT-1001 New in vitro data demonstrate site-specific integration of CFTR, a potential mutation-agnostic treatment...
View Article